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Evaporative emissionsFemale Sprague Dawley rats were exposed via inhalation to vapor condensates of either gasoline or
gasoline combined with various fuel oxygenates to assess potential immunotoxicity of evaporative
emissions. Test articles included vapor condensates prepared from ‘‘baseline gasoline’’ (BGVC), or gaso-
line combined with methyl tertiary butyl ether (G/MTBE), ethyl t-butyl ether (G/ETBE), t-amyl methyl
ether (G/TAME), diisopropyl ether (G/DIPE), ethanol (G/EtOH), or t-butyl alcohol (G/TBA). Target concen-
trations were 0, 2000, 10,000 or 20,000 mg/mg3 administered for 6 h/day, 5 days/week for 4 weeks. The
antibody-forming cell (AFC) response to the T-dependent antigen, sheep erythrocyte (sRBC), was used to
determine the effects of the gasoline vapor condensates on the humoral components of the immune sys-
tem. Exposure to BGVC, G/MTBE, G/TAME, and G/TBA did not result in signiﬁcant changes in the IgM AFC
response to sRBC, when evaluated as either speciﬁc activity (AFC/106 spleen cells) or as total spleen activ-
ity (AFC/spleen). Exposure to G/EtOH and G/DIPE resulted in a dose-dependent decrease in the AFC
response, reaching the level of statistical signiﬁcance only at the high 20,000 mg/m3 level. Exposure to
G/ETBE resulted in a statistically signiﬁcant decrease in the AFC response at the middle (10,000mg/m3)
and high (20,000 mg/m3) exposure concentrations.
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Introduction
The 1990 amendments to the Clean Air Act (CAA) mandated the
use of oxygenates in motor gasoline. In 1994, the U.S. Environmen-
tal Protection Agency (EPA) issued a ﬁnal rule under the CAA which
added new health effects information and testing requirements to
the Agency’s existing registration requirements. As described in
more detail in a companion paper (Henley et al., 2014),
requirements include inhalation exposures to evaporative
emissions of the gasoline or additive in question. The health end-
points include assessments for standard subchronic toxicity,
neurotoxicity, genotoxicity, immunotoxicity, developmental andreproductive toxicity, and chronic toxicity/carcinogenicity. The
results of chronic toxicity testing of gasoline and gasoline com-
bined with MTBE have already been reported (Benson et al.,
2011) and reported elsewhere in this issue are the ﬁndings for
genotoxicity (Schreiner et al., 2014), neurotoxicity (O’Callaghan
et al., 2014), reproductive toxicity (Gray et al., 2014), and develop-
mental toxicity testing in mice and rats (Roberts et al., 2014a;
Roberts et al., 2014b). This paper describes the results of immuno-
toxicity testing submitted to EPA.
Seven test materials were evaluated in 13 week toxicity studies.
They were vapor condensates prepared from an EPA described
‘‘baseline gasoline’’ (BGVC), as well as gasoline combined with
methyl tertiary butyl ether (G/MTBE), ethyl t-butyl ether (G/ETBE),
t-amyl methyl ether (G/TAME), diisopropyl ether (G/DIPE), ethanol
(G/EtOH), or t-butyl alcohol (G/TBA) (Henley et al., 2014). The
immunotoxicity studies described here were conducted with
satellite groups of the 13 week subchronic studies. The goal of
the studies was to provide information on the extent to which
the use of oxygenates in gasoline might alter the hazard of
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vehicles, compared to those from gasoline alone. The studies were
conducted in female rats because female rats elicit a more robust
immune response than male rats and have a greater sensitivity
for detecting an adverse effect of a compound should one occur.
Routine immunotoxicology evaluations conducted by the National
Toxicology Program (NTP) evaluate compounds only in female ani-
mals (Luster et al., 1988).
The IgM antibody-forming cell (AFC) response to the T-depen-
dent antigen sheep erythrocytes, also referred to as the plaque
assay, was the immunological assay conducted to evaluate the
effect of baseline gasoline and baseline gasoline/ oxygenate blend
vapor condensates on the immune response. For a single test, the
plaque assay has been shown to be the most comprehensive and
predictive assay for determining the immunotoxicological poten-
tial of a compound (Luster et al., 1992).
As background, sheep erythrocytes (sRBC) are a T-dependent
antigen, T cells, B cells, and macrophages (dendritic cells) are
required to function properly in order to obtain an antibody-
forming cell (AFC) response. If the test article affects any of these
cell types to a signiﬁcant degree, an altered response will be
observed which could be capable of modifying the humoral
immune response and, thus, has the potential for causing whole
animal immunotoxicity. As a result, the T-dependent IgM response
to sRBC is one of the most sensitive immunotoxicological assays
accepted by regulatory agencies currently in use.
The plaque assay is regarded as the ‘‘gold standard’’ for evaluat-
ing effects of compounds on humoral immunity. Although the
plaque assay is not considered to be an assay for other mechanisms
of immune response such as innate, T-cell independent, or cell-
mediated immunity, by utilizing a T-dependent antigen, it provides
valuable information on T-helper cells, macrophages, and B-/
plasma cells. As indicated above, if these cells are adversely
affected, then an effect on humoral immunity can be detected with
this assay. This assay is one of the tier I assays used by the NTP
(Luster et al., 1988).
2. Methods and materials
Seven separate inhalation studies involving exposures to vapor
condensates were conducted. Test materials included vapors of
baseline gasoline (BGVC) and BGVC combined with 10–20% (see
Henley et al., 2014) methyl t-butyl ether (G/MTBE), ethanol (G/
EtOH), t-amyl ethyl ether (G/TAME), ethyl t-butyl ether (G/ETBE),
diisopropyl ether (G/DIPE), or t-butyl alcohol (G/TBA). The in- life
phases of these studies (animal exposures) were conducted by
Huntingdon Life Sciences Princeton Research Center (PRC), East
Millstone, NJ, and the immunological evaluations were conducted
by ImmunoTox, Inc., Richmond, VA. The animals were satellite
groups of a larger subchronic toxicity study; the generation and
composition of the vapor concentrations and additional details
on the exposure methods are reported in companion articles
(Henley et al., 2014; Clark et al., 2014).
2.1. Experimental design
Each of the seven immunotoxicological satellite studies
consisted of ﬁve groups of animals: a vehicle control group, three
test material exposure groups (one of the gasoline vapor conden-
sates), and a positive control group. There were 10 female Sprague
Dawley rats in each of the groups. Animals were exposed by PRC
personnel to either vehicle (air only) or test material at exposure
levels of 2000, 10,000 or 20,000 mg/m3 via inhalation for 4 weeks
(5 days per week). Cyclophosphamide (CPS, CAS #6055-19-2,
purity 99.2%; from Sigma Chemical Company) was used as the
positive control. CPS was dissolved and diluted in phosphatebuffered saline to stock concentrations of 5.0 mg/mL. The positive
control animals received 50 mg/kg CPS, a known immunosuppres-
sive agent, administered intraperitoneally (i.p.) on the last 4 days
of exposure. These animals were not chamber exposed because
the purpose of the positive control group is merely to verify that
the assay can detect immunological effects. If the positive control
group fails to cause a signiﬁcant reduction in AFC, the assay is con-
sidered invalid and repeated.
Rats were immunized by ImmunoTox, Inc. personnel by intra-
venous injection of 2  108 sheep red blood cells (sRBC), four days
prior to sacriﬁce. One day after the last test material exposure and
four days after immunization with sRBC, rats were sacriﬁced and
PRC personnel aseptically removed the spleen from each animal,
weighed it, placed it in a collecting tube containing Earle’s
Balanced Salt Solution (EBSS) with 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES) and gentamicin solution and
shipped the spleens on ice in individual shipping containers at
2–8 C by overnight delivery to ImmunoTox laboratories for immu-
nological evaluation. Upon receipt, spleens were further processed
for determination of IgM antibody response.
2.2. Terminal body and organ weights
The terminal body weights were obtained by PRC personnel,
who also collected blood (serum) samples (orbital collection anes-
thetized via carbon dioxide/oxygen inhalation) and then sacriﬁced
(carbon dioxide inhalation) the animals on the day after the ﬁnal
exposure. The serum samples were frozen (70 C). The thymuses
were removed, weighed and preserved in formalin for possible
histopathology.
2.3. Splenocyte preparation
Upon arrival at the ImmunoTox testing facility, single-cell sus-
pensions were prepared from each spleen using a Stomacher 80
Lab Blender. Cell suspensions were then centrifuged and resus-
pended in EBSS with HEPES buffer in a 6-ml volume, from which
1:50 and 1:150 dilutions were prepared. Viability of splenocytes
was determined using propidium iodide (PI) and the Coulter EPICS
XL-MCL Flow Cytometer.
2.4. Spleen lgM antibody response to the T-dependent antigen, sRBC-
day 4 response
The primary IgM response to sheep erythrocytes was measured
using a modiﬁed hemolytic plaque assay of Jerne (Jerne et al.,
1974), as detailed by White et al., 2010. A 0.1-ml aliquot of spleen
cells from each suspension was added to separate test tubes, each
containing 25 ll guinea pig complement, 25 ll sRBC, and 0.5 ml of
warm agar (0.5%). After thoroughly mixing, each test tube mixture
was plated onto a separate petri dish, covered with a microscope
cover slip, and incubated at approximately 36–38 C for 3 h.
Spleen cell number, following lysis of RBC, was performed on
the 6-ml samples using a Model Z1 Coulter Counter. The spleen
weight, cells/spleen, antibody forming cells (AFC)/106 spleen cells,
and AFC/spleen were determined. The plaques that developed
were counted using a Bellco plaque viewer. For each spleen, 2 dilu-
tions (1:50 and1:150) were prepared. At the time of counting, each
plate was examined. Routinely, the plate that had between 100 and
300 plaques was counted. When the number of plaques is in excess
of 350 plaques per plate, it becomes difﬁcult to obtain an accurate
count using the Bellco viewer. A plaque, occurring from the lysis of
sRBC, is elicited as a result of the interaction of complement and
antibodies (produced in response to the i.v. immunization)
directed against sRBC. Each plaque is generated from a single
IgM antibody-producing B cell, permitting the number of AFC
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expressed as speciﬁc activity (AFC/106 spleen cells) and total
spleen activity (AFC/spleen).
In accordance with practices of NTP immunotoxicology assays,
these plaque forming assay results were not adjusted for spleen
cell viability. In mixed cell populations, lymphocytes, particularly
those antibody forming cells (plasma cells) making antibody to
sheep erythrocytes die off more slowly than more fragile polymor-
phonuclear cells White et al., 2010). Thus, correcting for individual
cell viability in a mixed population can artiﬁcially inﬂate plaque
forming cell values.
2.5. Data handling and statistical analysis
The data obtained in this studywere ﬁrst tested for homogeneity
of variances using the Bartlett’s Chi Square Test (Bartlett, 1937).
Homogeneous data were evaluated by a parametric one-way anal-
ysis of variance (Kruskal andWallis, 1952). When signiﬁcant differ-
ences occurred, exposed groups were compared to the vehicle
control group using the Dunnett’s t Test (Dunnett, 1955). Non-
homogeneous data were evaluated using a non-parametric analysis
of variance (Kruskal andWallis, 1952).When signiﬁcant differences
occurred, exposed groups were compared to vehicle control group
using the Gehan-Wilcoxon Test (Gross and Clark, 1975) when
appropriate. The Jonckheere’s Test (Hollander and Wolfe, 1973)
was used to test for exposure level-related trends across the vehicle
and exposed groups. The positive control was compared to the vehi-
cle control group using the Student’s t Test (Sokal and Rohlf, 1981).
The criteria for accepting the results of the positive control in the
assay were a statistically signiﬁcant (p < 0.05) decrease in the
response as compared to the vehicle control group.
2.6. Compliance
These studies were conducted in accordance with the United
States Environmental Protection Agency’s (EPA) Good Laboratory
Practice Standards (US EPA, 1994), and complied with all appropri-
ate parts of the Animal Welfare Act Regulations (USDA, 1989,
1991). The study also met the requirements of EPA’s guidelines
for inhalation toxicity and immunotoxicity screening (US EPA,
1998a,b).Table 1
Spleen antibody-forming cell response to T-dependent antigen sheep erythrocytes in fema
Test material Exposure group Body weight (g) Spleen weight (mg)
BGVC Vehicle 247.8 ± 3.6 615 ± 38
2000 mg/m3 258.0 ± 5.2 647 ± 26
10,000 mg/m3 250.0 ± 5.7 600 ± 23
20,000 mg/m3 245.7 ± 2.7 675 ± 102
Positive control 224.4 ± 5.5** 265 ± 10**
G/MTBE Vehicle 248.3 ± 6.1 646 ± 35
2000 mg/m3 256.9 ± 3.3 637 ± 34
10,000 mg/m3 242.5 ± 6.5 574 ± 25
20,000 mg/m3 254.8 ± 7.2 651 ± 43
Positive control 231.3 ± 9.2 283 ± 18**
G/TAME Vehicle 255.7 ± 5.1 587 ± 24
2000 mg/m3 252.0 ± 5.8 623 ± 39
10,000 mg/m3 261.9 ± 8.2 676 ± 27
20,000 mg/m3 255.8 ± 6.3 618 ± 25
Positive control 238.5 ± 8.9 291 ± 16**
G/TBA Vehicle 262.1 ± 5.1 676 ± 31
2000 mg/m3 255.4 ± 6.7 630 ± 27
10,000 mg/m3 252.6 ± 6.8 614 ± 27
20,000 mg/m3 254.2 ± 5.2 611 ± 24
Positive control 243.4 ± 5.0* 304 ± 12**
* Statistically signiﬁcant from vehicle control at p 6 0.05.
** Statistically signiﬁcant from vehicle control at p 6 0.01.
a Excludes outlier in BGVC high dose group with IgM AFC/106 value of 216 and AFC/s3. Results
3.1. Terminal body and organ weights
No statistically signiﬁcant effect was observed on terminal body
weights in any of the vapor condensate exposure groups, as com-
pared to the corresponding vehicle controls. In addition, exposure
to the test materials in the seven studies did not signiﬁcantly affect
spleen or thymus weights when evaluated either as absolute or rel-
ative weight, with the exception of the G/DIPE exposed animals.
When evaluated as relative weight, there was a statistically signif-
icant increase in the spleen of 21% at the low dose G/DIPE exposure
level when compared to the vehicle control. However, the effect on
relative weight was not dose dependent and is not considered to be
biologically signiﬁcant. Furthermore, there was no effect on the
relative weight of the thymus in G/DIPE exposed animals.
Treatment with the positive control, cyclophosphamide, signif-
icantly decreased both absolute and relative spleen and thymus
weights in all of the studies, compared to the vehicle controls. Val-
ues for absolute spleen weight were depressed between 50–57%
and between 45–53% for relative spleen weight. Absolute thymus
weights were depressed 73–80% and between 71% and 79% for rel-
ative thymus weights.3.2. Spleen IgM antibody forming cell response
The spleen IgM antibody-forming cell response, i.e. plaque
assay, was evaluated on spleens removed 1 day after the last expo-
sure, which was Day 4 after antigen sensitization. Day 4 after anti-
gen sensitization is the peak day for the sRBC IgM AFC response in
rats. Female rats were sensitized in the morning and also sacriﬁced
in the morning. Viabilities were conducted on all cell suspensions
and ranged from 70% to greater than 95% for BGVC, 87% (G/MTBE),
84% (G/TAME, G/EtOH, G/ETBE), 71% (G/TBA), and 70% (G/DIPE).
There were no statistically signiﬁcant differences in spleen cell
numbers resulting from exposure to any of the test materials
(Tables 1 and 2), consistent with the lack of effect on spleen
weights noted above. (There was a slight, albeit not statistically
signiﬁcant increase in spleen cell number in the low dose G/DIPE
group, which is not consistent with its lower spleen weights).le rats exposed to BGVC, G/MTBE, G/TAME, or G/TBA via inhalation for 4 weeks.
Spleen cells (107) IgM AFC/106 spleen cells IgM AFC/spleen (103)
53.18 ± 2.15 1639 ± 408 880 ± 209
62.26 ± 2.35 1540 ± 194 980 ± 143
55.82 ± 4.02 1687 ± 235 903 ± 120
57.96 ± 3.33 1175 ± 111a 685 ± 77a
9.69 ± 0.41** 3 ± 3** 0 ± 0**
72.09 ± 3.82 1646 ± 218 1162 ± 137
76.52 ± 4.07 1128 ± 190 887 ± 171
65.13 ± 2.81 1490 ± 282 966 ± 185
76.28 ± 5.97 1680 ± 199 1245 ± 122
10.65 ± 0.74** 0 ± 0** 0 ± 0**
60.71 ± 3.45 1560 ± 342 928 ± 184
64.78 ± 5.15 1250 ± 194 785 ± 114
68.09 ± 5.01 1384 ± 208 908 ± 132
55.34 ± 3.00 1514 ± 289 874 ± 177
10.41 ± 0.52** 0 ± 0** 0 ± 0**
85.01 ± 5.36 1863 ± 308 928 ± 184
83.78 ± 3.20 1734 ± 350 785 ± 114
78.71 ± 5.28 1960 ± 408 908 ± 132
74.30 ± 4.03 1759 ± 368 874 ± 177
14.46 ± 0.64** 27 ± 9** 4 ± 1**
pleen value of 123.
Table 2
Spleen antibody-forming cell response to T-dependent antigen sheep erythrocytes in female rats exposed to G/ETOH, G/ETBE or G/DIPE via inhalation for 4 weeks.
Test material Exposure group Body weight (g) Spleen weight (mg) Spleen cells (107) IgM AFC/106 spleen cells IgM AFC/spleen (103)
G/EtOH Vehicle 242.1 ± 4.4 625 ± 39 74.34 ± 5.29 974 ± 259 705 ± 161
2000 mg/m3 243.8 ± 6.7 645 ± 38 70.36 ± 2.86 692 ± 137 477 ± 93
10,000 mg/m3 243.7 ± 4.9 586 ± 28 65.44 ± 3.32 505 ± 148 347 ± 111
20,000 mg/m3 240.1 ± 7.2 591 ± 34 67.97 ± 6.29 143 ± 29** 98 ± 18**
Positive control 223.2 ± 7.6* 271 ± 14** 11.60 ± 0.86** 0 ± 0** 0 ± 0**
G/ETBE Vehicle 259.0 ± 5.0 597 ± 37 71.48 ± 4.48 556 ± 76 391 ± 48
2000 mg/m3 263.0 ± 3.2 608 ± 41 74.21 ± 3.69 576 ± 94 427 ± 72
10,000 mg/m3 259.4 ± 4.0 608 ± 25 72.95 ± 1.27 136 ± 23** 100 ± 17**
20,000 mg/m3 250.3 ± 3.5 603 ± 17 72.34 ± 2.78 153 ± 39** 117 ± 35
Positive control 247.0 ± 4.0 299 ± 17** 15.79 ± 1.21** 0 ± 0** 0 ± 0**
G/DIPE Vehicle 251.6 ± 4.3 544 ± 24 62.65 ± 2.50 688 ± 128 440 ± 95
2000 mg/m3 254.5 ± 4.9 667 ± 30 75.17 ± 4.34 657 ± 166 503 ± 137
10,000 mg/m3 249.8 ± 3.5 579 ± 33 65.87 ± 3.29 553 ± 143 377 ± 106
20,000 mg/m3 247.9 ± 5.4 604 ± 39 64.82 ± 3.92 252 ± 44** 159 ± 26**
Positive control 228.7 ± 4.6** 267 ± 14** 12.52 ± 0.73 0 ± 0** 0 ± 0**
* Statistically signiﬁcant from vehicle control at p 6 0.05.
** Statistically signiﬁcant from vehicle control at p 6 0.01.
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spleen cell numbers in all of the studies compared to the vehicle
control group, ranging from 78% depression in the G/ETBE positive
control group to 85% in G/MTBE positive control animals.
The functional results from the AFC assay for the BGVC, G/
MTBE, G/TAME and G/TBA groups are shown in Table 1. There were
no statistically signiﬁcant differences in the IgM antibody-forming
cell response between animals exposed to these vapor condensates
and their corresponding vehicle control group when evaluated
either as speciﬁc activity (AFC/106 spleen cells) or as total spleen
activity (AFC/spleen). (In the BGVC high dose group there was
one animal which had an IgM AFC/106 value of 216 and an AFC/
spleen value of 123, which was considered a signiﬁcant enough
outlier that it was not included in the analysis. Furthermore, there
was no signiﬁcant difference in the trend analysis when evaluated
by the Jonckheere’s Test.
The results from the AFC assay for the G/EtOH, G/ETBE, and G/
DIPE groups are summarized in Table 2. Dose related decreases
in IgM antibody forming cell response to the T-dependent antigen
sRBC, were observed in the G/EtOH, G/ETBE, and G/DIPE exposed
groups when the data were evaluated as either speciﬁc activity
or as total spleen activity. For both parameters, exposure produced
a reduced response at all exposure levels, but only the high dose
reached a level of statistical signiﬁcance. The response of the high
dose group was suppressed 85% and 63% for the G/EtOH and G/
DIPE groups, respectively, and 86% and 64% (G/EtOH v G/DIPE)
when evaluated as total spleen activity. While the overall response
of the DIPE animals was somewhat lower than had been observed
in the past, the positive and negative control animal responses are
consistent with the range of responses observed with the Sprague
Dawley outbred strain of rats.
Statistically signiﬁcant decreases in IgM antibody forming cell
response were observed at the mid and high doses in the G/ETBE
exposed group (Table 2). When evaluated as speciﬁc activity, the
responses of the mid and high dose groups were suppressed 76%
and 72%, respectively, and 64% and 70% (mid v high) when eval-
uated as total spleen activity. There was no signiﬁcant difference
in the trend analysis when evaluated by the Jonckheere’s Test. As
anticipated, the positive control, CPS, produced a signiﬁcant
decrease in both speciﬁc activity and total spleen cell activity
when compared to the vehicle control animals (Tables 1 and
2). The results of both the positive and negative (vehicle) con-
trols were consistent with the historical controls for the
laboratory.4. Conclusions and discussion
Exposure of female Sprague Dawley rats to the gasoline vapor
condensates BGVC, G/MTBE, G/TAME and G/TBA 6 h/day, 5 days/
week for 4 weeks did not result in alterations of the humoral
immune response as evaluated in the IgM antibody-forming cell
response to the T-dependent antigen sheep erythrocytes. There
were no statistically signiﬁcant effects on spleen weight, spleen
cell number, or IgM antibody production when evaluated as either
speciﬁc activity or as total spleen activity. Based on the immuno-
logical parameters evaluated, under the experimental conditions
of these studies, the four vapor condensates did not adversely
affect the humoral immune response of the test animals. Further-
more, the addition of MTBE, TAME or TBA did not affect the
immune AFC response of gasoline vapor condensate alone.
There was statistically signiﬁcant depression of the humoral
immune response for three of the vapor condensates: G/EtOH
and G/DIPE at the 20,000 mg/m3 dose and G/ETBE at the
10,000 mg/m3 and 20,000 mg/m3 doses. Plaque forming cell assays
conducted in rats following ethanol administered alone by the oral
route have shown decreased antibody responses in sheep red
blood cells (Loose et al., 1975; Razani-Boroujerdi et al., 1994).
However the responses to ethanol have been somewhat contradic-
tory and may depend on the age of the animal, amount of ethanol
consumed, and nutritional composition of the administered diet
(Loose et al., 1975; Razani-Boroujerdi et al., 1994).
There are no peer-reviewed published studies suggesting either
ETBE or DIPE are capable of causing immunotoxicity, including
hypersensitivity responses. An unpublished evaluation of ETBE in
the guinea pig minimization assay with induction via intradermal
injection of a 10% solution, followed by challenge using an
occluded patch with 100% ETBE, did not provoke any signs of cuta-
neous sensitization (no positive controls were used in the study;
European Chemicals Agency website). DIPE did not elicit a positive
response in an unpublished laboratory study using the mouse local
lymph node assay (European Chemicals Agency website).
In conclusion, gasoline vapor condensates and condensates of
gasoline mixed with MTBE, TAME and TBA were negative in the
plaque assay indicating that, similar to gasoline vapor condensate
alone, the addition of these additives do not affect rat humoral
immunity. Gasoline mixed with EtOH, ETBE and DIPE elicited posi-
tive responses thus suggesting that the addition of EtOH, ETBE, or
DIPE does depress the rat humoral response as compared to the
response from gasoline vapor condensate alone. The no observed
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G/EtOH and G/DIPE and 2000 mg/m3 for G/ETBE under the
described test conditions.
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